PuraPharm (1498) Stock Overview
An investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
1498 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PuraPharm Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.35 |
| 52 Week High | HK$0.65 |
| 52 Week Low | HK$0.34 |
| Beta | 0.12 |
| 1 Month Change | -2.78% |
| 3 Month Change | -18.60% |
| 1 Year Change | -32.69% |
| 3 Year Change | -72.00% |
| 5 Year Change | -50.00% |
| Change since IPO | -90.86% |
Recent News & Updates
Recent updates
Increases to PuraPharm Corporation Limited's (HKG:1498) CEO Compensation Might Cool off for now
May 20
PuraPharm Corporation Limited's (HKG:1498) Shares Lagging The Industry But So Is The Business
Feb 21Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)
Feb 06Is PuraPharm (HKG:1498) A Risky Investment?
Sep 28PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?
Nov 02Is PuraPharm (HKG:1498) A Risky Investment?
Aug 23PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues
Apr 01How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?
Dec 27
Shareholder Returns
| 1498 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 2.9% | 4.8% | 1.6% |
| 1Y | -32.7% | 91.0% | 36.3% |
Return vs Industry: 1498 underperformed the Hong Kong Pharmaceuticals industry which returned 91% over the past year.
Return vs Market: 1498 underperformed the Hong Kong Market which returned 36.3% over the past year.
Price Volatility
| 1498 volatility | |
|---|---|
| 1498 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 2.9% |
Stable Share Price: 1498 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1498's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 469 | Abraham Chan | www.purapharm.com |
PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names.
PuraPharm Corporation Limited Fundamentals Summary
| 1498 fundamental statistics | |
|---|---|
| Market cap | HK$187.27m |
| Earnings (TTM) | -HK$38.56m |
| Revenue (TTM) | HK$346.76m |
Is 1498 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1498 income statement (TTM) | |
|---|---|
| Revenue | HK$346.76m |
| Cost of Revenue | HK$159.76m |
| Gross Profit | HK$187.00m |
| Other Expenses | HK$225.56m |
| Earnings | -HK$38.56m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.072 |
| Gross Margin | 53.93% |
| Net Profit Margin | -11.12% |
| Debt/Equity Ratio | 333.3% |
How did 1498 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/15 20:40 |
| End of Day Share Price | 2026/01/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PuraPharm Corporation Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ajeya Patil | Evaluate Research Limited |